Ziftomenib - What is Komzifti a medicine for?

Ziftomenib - Komzifti is a novel medicine indicated for the treatment of adult patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Acute myeloid leukemia, the most common form of acute leukemia in adults, is characterized by the bone marrow producing abnormal myeloblasts (such as white blood cells, red blood cells, or platelets), resulting in a lack of normal cells in the blood. NPM1 mutations are considered to be the most common genetic alterations in AML, accounting for approximately 30% of all cases, and the menin pathway is considered to be the main driver of various genetic alterations in this disease.

Komzifti's active ingredient, ziftomenib, is a menin inhibitor that blocks the oncogenic activity of mutant NPM1 by disrupting its interaction with the lysine [K]-specific transferase 2A (KMT2A) protein. This mechanism effectively inhibits the growth and spread of leukemia cells, providing a new treatment option for refractory patients.

The use of ziftomenib is particularly important for patients with relapsed or refractory AML, as these patients often have no effective alternative treatment options. The drug is taken orally once daily until disease progression or unacceptable toxicity occurs. According to clinical trial data, the incidence of common adverse reactions of ziftomenib is over 20%, mainly including infection by unknown pathogens, bleeding, diarrhea, nausea, fatigue, edema, bacterial infection, musculoskeletal pain, differentiation syndrome, pruritus, fever, neutropenia, and elevated transaminases.

In conclusion, zitumenib offers new hope as an innovative treatment option for adults facing relapsed or refractory NPM1-mutated acute myeloid leukemia Through its unique mechanism of action, ziftomenib not only brings new treatment options to patients, but also opens up new directions for future research on AML.

Reference materials:https://www.drugs.com/komzifti.html